Heron Therapeutics (HRTX) Non-Current Assets (2010 - 2026)

Heron Therapeutics has reported Non-Current Assets for 17 years, with the latest figure at $17.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 24.79% year-over-year to $17.2 million; the trailing twelve-month figure through Mar 2026 stood at $75.8 million (down 23.94% YoY), and the FY2025 full-year result was $17.8 million, down 26.2% from the prior year.
• Non-Current Assets for Q1 2026 stood at $17.2 million, down from $17.8 million in the prior quarter.
• The five-year high for Non-Current Assets was $51.1 million in Q1 2022, with the low at $17.2 million in Q1 2026.
• Historically, Non-Current Assets has averaged $32.3 million across 5 years, with a median of $32.0 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Assets surged 32.95% — and 2024, when it retreated 28.46%.
• Heron Therapeutics' Non-Current Assets stood at $45.5 million in 2022, then declined by 25.89% to $33.7 million in 2023, then dropped by 28.46% to $24.1 million in 2024, then declined by 26.2% to $17.8 million in 2025, then retreated by 3.25% to $17.2 million in 2026.
• The last three Non-Current Assets figures came in at $17.2 million (Q1 2026), $17.8 million (Q4 2025), and $19.6 million (Q3 2025), per Business Quant data.